Top Drugs and Companies: Darzalex Dominates
Sales of the biggest orphan, Johnson & Johnson’s multiple myeloma drug Darzalex (daratumumab), will exceed $16 billion by the end of the decade – exceeding the sales peak reached by BMS/Pfizer’s clot-buster Eliquis (apixaban). Darzalex secures J&J firmly atop the list of biggest companies by 2030 orphan drug sales.
WW Orphan Prescription Drug Sales in 2030: Top 10 Companies
Darzalex may also fall within the crosshairs of the Inflation Reduction Act’s lower negotiated prices for the costliest Medicare drugs.
Yet Darzalex may also fall within the crosshairs of the Inflation Reduction Act’s lower negotiated prices for the costliest Medicare drugs, just as Eliquis has done. J&J is seeking to protect it by arguing that its subcutaneous Faspro formulation is a new medicine, but it’s a grey area. Meanwhile, other blood cancer mega-orphans, including AbbVie’s Imbruvica and AstraZeneca’s Calquence will also face
IRA-negotiated pricing this decade. Calquence’s forecast sales of close to $5 billion nevertheless keep it just about within the 2030 top ten best-selling orphans; its IRA price won’t kick in until January 2027.
Top 10 Selling Orphan Drugs in 2030 by Worldwide Sales
